Clinical Trial Results:
Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.
Summary
|
|
EudraCT number |
2013-002825-52 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Jul 2023
|
First version publication date |
21 Jul 2023
|
Other versions |
|
Summary report(s) |
Statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.